Boston Scientific SG&A decreased by 2.9% to $1.78B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.5%, from $1.60B to $1.78B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 12.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.12B | $1.07B | $1.15B | $1.06B | $1.17B | $1.13B | $1.16B | $1.22B | $1.35B | $1.24B | $1.38B | $1.36B | $1.45B | $1.56B | $1.61B | $1.60B | $1.72B | $1.74B | $1.83B | $1.78B |
| QoQ Change | — | -4.9% | +8.2% | -8.1% | +9.9% | -2.8% | +2.7% | +4.5% | +11.4% | -8.3% | +11.0% | -1.1% | +6.0% | +8.0% | +3.2% | -0.9% | +7.5% | +1.5% | +5.3% | -2.9% |
| YoY Change | — | — | — | — | +3.9% | +6.2% | +0.9% | +14.6% | +16.2% | +9.7% | +18.6% | +12.3% | +6.8% | +25.8% | +16.9% | +17.1% | +18.7% | +11.5% | +13.8% | +11.5% |